Boston Scientific reports strong growth in second quarter of 2017

Boston Scientific has announced its financial results for the second quarter of 2017, during which it recorded a sales total of $2.26 billion (1.73 billion pounds).

This represented a year-on-year increase of six percent in reported terms, or seven percent on an operational basis, while GAAP earnings rose to $146 million from a loss of $207 million during the same period last year.

Revenue growth was reflected across all segments, including its MedSurg, cardiovascular and rhythm management divisions, with particularly strong performances seen in the US and the Asia-Pacific, Middle East and Africa regions.

Key highlights of the quarter included the acquisition of the structural heart company Symetis, as well as the reporting of positive clinical trial data for the Lotus valve system and Watchman left atrial appendage closure device.

The company now estimates revenue for the full year 2017 to be in a range of $8.89 to $8.99 billion, which would represent a year-on-year increase of six or seven percent.

Mike Mahoney, chairman and chief executive officer at Boston Scientific, said: "Our team continues to drive results while also investing in multiple high-growth markets where we expect our portfolio will have a meaningful impact on customers and their patients."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.